Global biotechnology company NodThera is developing a new class of potent and selective small-molecule NLRP3 inhibitors for the treatment of diseases driven by chronic inflammation, such as ...
The NLRP3 inflammasome is a key inflammation driver linked to central nervous system (CNS) disorders, metabolic diseases, and aging-related conditions. JOTROL, Jupiter’s flagship product ...
Adhering to a high calorie Western diet, for example ... acid turned down the activity of a protein complex called the NLRP3 inflammasome. Inflammasomes, as the name suggests, are mechanisms ...
Jupiter, Florida, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback